

Trindade MAB¹Careta MF²

ACUTE METHEMOGLOBINEMIA INDUCED BY DAPSONE

ABSTRACT

Acute methemoglobinemia is an uncommon but potentially treatable disorder in which patient can present with dramatic signs and symptoms. The early diagnosis and treatment are essential to prevent this fatal medicine reaction.

INTRODUCTION

The methemoglobinemia is a condition in which an abnormal proportion of the iron in heme moiety of the hemoglobin is oxidized to the ferric state leading to impaired oxygen transport and anemic hypoxia.

Methemoglobinemia refers to any increase in normal methemoglobin levels. It can cause tissue ischemia and death. It results most commonly from a toxic exposure, but in rare cases it can be hereditary³.

Methemoglobin levels of 10% to 20% usually produce cyanosis. Levels of 20% to 50% will cause symptoms such as respiratory distress, dizziness, headache, and fatigue. Lethargy and stupor develop at levels around 50% and death may occur around 70%². Any patient with cyanosis unresponsive to oxygen who has a normal PaO₂, should be evaluated for methemoglobinemia.

About 40 substances have been implicated in causing this condition, the most prominent being dapsone, nitrates, prilocaine, antimalarials and sulfonamids. Dapsone is used to treat several systemic inflammatory diseases, such as leprosy³. The introduction of treatment

Trindade MAB, Careta MF. Acute Methemoglobinemia induced by dapsone case report in leprosy treatment. *Hansen Int.* 2008; 33 (2): 31-34.

complicated by methemoglobinemia, is an uncommon side effect of dapsone, the incidence related is around 5-6,5% of adverse reactions of leprosy treatment¹.

CASE DESCRIPTION

This report describes the case of a female 25 years old, receptionist, that showed complications by methemoglobinemia when started the treatment for indeterminate leprosy with rifampicine and dapsone. She looked for ambulatory assistance on the fourth day after 100 mg/day of dapsone because her hands, nose and feet are blue and slow headache. After about one hour on physical examination showed a lethargic girl with respiratory distress, fatigue and dizziness with normal vital signs and normal size pupils that were reactive to light. The conjunctivae were not pale and the scleras were not icteric. Her clinical course included bluish discoloration of lips and limbs, a high PaO₂ in the presence of cyanosis. The clinical history led to suspicion of methemoglobinemia.

Recebido em 27/11/2008.

Última correção em 08/04/2009.

Aceito em: 20/05/2009.

1 Pesquisadora científica da Secretaria de Saúde do Estado de São Paulo.

2 Médica residente do Programa de Dermatologia - USP-SP.

Patient was underwent oxygen mask (10l O₂/min). Therefore, methemoglobinemia secondary to dapsone intoxication was assumed, and 1 mg/kg methylene blue diluted with 100 ml normal saline was given IV over 30 min. Laboratory results showed methemoglobin level to be 4.0 g/dL (40%). The investigation for G6PD deficiency had normal resulted.

In this patient symptoms improve about half hour and she had discharge in the same day. After she had the medications changed to an alternative treatment for leprosy with out dapsone (rifampicin, ofloxacin and minocycline) for one month.

DISCUSSION

In the present patient, normal oxygen saturation on the first arterial blood gas along with cyanosis and mild tachypnea diverted the attention to methemoglobinemia. Methemoglobin level is useful to confirm the diagnosis, but it is not as important as the patient's clinical status for determining early treatment.

In dapsone poisoning, varying clinical presentations such as severe cyanosis, restlessness, dyspnea, extensive hemolysis, anemia and/or serious central nervous system dysfunction are expected. In addition, nausea and vomiting, tachycardia and elevation of blood pressure have been reported^{2,5,11}. Dapsone overdose is often dangerous and potentially lethal. Methemoglobinemia resulting from the ingestion of dapsone has been described as cyanosis without

respiratory distress. The cyanosis is unresponsive to oxygen administration.

For symptomatic patients, initial treatment includes administering oxygen. If no have improve and/or if have history of contact with methemoglin-inducer substances the treatment of choice is methylene blue^{3,11}. It is administered typically in doses of 1 to 2 mg/kg of body weight intravenously. Symptoms should improve rapidly^{2,4}. Repeat doses may be indicated if symptoms persist, as may occur if there is continued absorption of the methemoglobin-inducer⁸. In the present case, single-dose administration of the antidote was sufficient.

In cases of treatment failure with methylene blue, hyperbaric oxygen therapy and exchange transfusions can be considered. Methylene blue is generally contraindicated in people who have a genetic defect in natural reduction systems, including those with G₆PD deficiency witch are also prone to methylene blue-induced hemolysis. Due to the long half-life and unique methemoglobin-inducing metabolites of dapsone, cimetidine may be used to block production of the toxic metabolites, thereby limiting the duration of dapsone-related methemoglobinemia¹².

This report intend to show the importance of the diagnostic and treatment of this adverse effect of dapsone. Principally, because the majority of patients with leprosy are treated with dapsone in the basic units of health, that cannot have suport to conduct this letal and reversible emergency.

REFERENCES

- 1 Goulart IMB, Arbex GL. Adverse effects of multidrug therapy in leprosy patients a five year survey at a Health Center of the Federal University of Uberlândia. *Revista da Sociedade Brasileira de Medicina Tropical* 2002; 35(5): 453-60.
- 2 Kraemer T, Paul LD, Jochum CH, Maurer HH. Acute poisoning with dapsone, a case report. *Toxichem Krintech* 2002; (69): 80-5.
- 3 Turner MD, Karlis V, Glickman RS. The recognition, physiology, and treatment of medication induced methemoglobinemia: a case report. *Anesth Prog* 2007; (54): 115-7.
- 4 Prasad R, Das BP, Singh R, Sharma KK. Dapsone induced methemoglobinemia, sulfhemoglobinemia and hemolytic anemia: a case report with note on treatment strategies. *Ind J Pharm* 2002; (34): 283-5.
- 5 Woodhouse KW, Henderson DB, Charlton B, Peaston RT, Rawlins MD. Acute dapsone poisoning: clinical features and pharmacokinetic studies. *Hum Toxicol* 1983 (2): 507-10.
- 6 Elonen E, Neuvonen PJ, Halmekoski J, Mattila MJ. Acute dapsone intoxication: a case with prolonged symptoms. *Clin Toxicol* 1979; (14): 79-85.
- 7 Prasad R, Singh R, Mishra OP, Pandey M. Dapsone induced methemoglobinemia: intermittent vs continuous Intravenous Methylene Blue Therapy. *Indian Journaul of Pediatrics* 75, março, 2008, 245-247.
- 8 Dawson AH, Whyte IM. Management of dapsone poisoning complicated by methaemoglobinaemia, *Med Toxicol Adverse Drug Exp* 4 1989: 387-92.
- 9 Shadnia S, Rahimi M, Moeinsadat G, Vesal M. Donyavi and M. Abdollahi, acute methemoglobinemia following attempted suicide by dapson, *Archives of Medical Research* 2006 (37): 410-14.
- 10 Nancy E. Methemoglobinemia. *Journal of Emergency Nursing* 2007; (3): 172-74.

11 Graham Jr WR. Adverse effects of dapsone. *Int J Dermatol* 1975; 14 (7): 494–500.

12 Emedicine Methemoglobinemia. Available from: <http://www.emedicine.com/EMERG/topic313.htm>.

